000			01607 a2200409 4500
005			20250513192438.0
264		0	_c19991021
008			199910s 0 0 eng d
022			_a0006-291X
024	7		_a10.1006/bbrc.1999.1312 _2doi
040			_aNLM _beng _cNLM
100	1		_aFernandez, P C
245	0	0	_aCeramide synergizes with phorbol ester or okadaic acid to induce IkappaB degradation. _h[electronic resource]
260			_bBiochemical and biophysical research communications _cSep 1999
300			_a63-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAnimals
650	0	4	_aCell Line
650	0	4	_aCeramides _xadministration & dosage
650	0	4	_aDNA-Binding Proteins _xmetabolism
650	0	4	_aDrug Synergism
650	0	4	_aEnzyme Activation _xdrug effects
650	0	4	_aHumans
650	0	4	_aI-kappa B Proteins
650	0	4	_aNF-KappaB Inhibitor alpha
650	0	4	_aNF-kappa B _xmetabolism
650	0	4	_aOkadaic Acid _xadministration & dosage
650	0	4	_aProtein Kinase C _xmetabolism
650	0	4	_aSecond Messenger Systems
650	0	4	_aSphingomyelin Phosphodiesterase _xmetabolism
650	0	4	_aT-Lymphocytes _xdrug effects
650	0	4	_aTetradecanoylphorbol Acetate _xadministration & dosage
650	0	4	_aTheileria parva _xpathogenicity
700	1		_aDobbelaere, D A
773	0		_tBiochemical and biophysical research communications _gvol. 263 _gno. 1 _gp. 63-7
856	4	0	_uhttps://doi.org/10.1006/bbrc.1999.1312 _zAvailable from publisher's website
999			_c10443591 _d10443591